… arterial smooth muscle cells (HPASMCs) isolated from pulmonary arterial hypertension (PAH)
patients. Whilst RNA was isolated from PAH (n=3) and non-PAH controls (n=3), these …

… could be confused with pathologies such as chronic obstructive pulmonary disease [67,68]. …
prevalence of pulmonary hypertension and right ventricular dysfunction in those patients and …

… We will first focus on the well-established natriuretic peptides, … sST2 is a marker of mechanical
stress and ventricular … Apart from clinical studies, recent advances in pre-clinical models …

… and N‐terminal pro‐brain natriuretic peptide on laboratory … /dt max /IP, a surrogate marker
of intrinsic RV contractility, 18 as … There is strong preclinical and clinical data that demonstrate …

… OSAS patients after CPAP treatment, which was consistent with our findings. Brain natriuretic
peptide … As such, it is a potential marker for screening preclinical cardiovascular damage in …

… These clinical and preclinical observations suggest that NPs … can increase cerebral blood
flow and reduce inflammatory markers (… Patients with AIDS-related dementia, cancer, chronic …

… tachyarrhythmia Pulmonary hypertension Cardioversion/ICD … to be the most significant
markers that reveal the develop… In preclinical CV damages, NPs elevate early as an endogenic …

… and more pre-clinical and clinical studies are demanded. … in patients after acute PE and
may serve as a potential marker … Natriuretic peptides are released from cardiac myocytes in …

… atrial natriuretic peptide and N-terminal pro-brain natriuretic … CILP1 as a cardiac fibrosis
marker. However, blood samples … of RV maladaptation used in preclinical and clinical studies. In …

… ventricular hypertrophy, pulmonary hypertension, and significant … as useful markers to
discriminate between patients with … NPs to specifically detect preclinical cardiac abnormalities. The …